Why is Warner Bros. Discovery splitting in two?
How will Amazon’s $20B Pennsylvania cloud investment affect AI?
What caused Tesla’s stock downgrades after Musk-Trump feud?
Why did OpenAI hit $10 billion in annual recurring revenue?
How will Trump’s National Guard deployment impact LA protests?
What are the effects of US-China trade talks in London?
Why is Apple redesigning iOS with 'Liquid Glass' interface?
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required
benzinga.com/news/fda/25/06/45842278/fda-pushes-pause-on-axsome-fibromyalgia-drug-new-trial-required
The U.S. Food and Drug Administration (FDA) sent a “refusal to file” letter to Axsome Therapeutics, Inc. (NASDAQ:AXSM) on Monday regarding its AXS-14 (esreboxetine) treatment of fibromyalgia.
The FDA states that upon preliminary review, the New Drug Application (NDA) was not sufficiently…
This story appeared on benzinga.com, 2025-06-09 16:39:11.